Eli Lilly and Company LLY
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -9.08% | -4.07% | 11.42% | 18.91% | -1.40% |
| Total Depreciation and Amortization | 2.06% | 4.91% | -13.10% | 24.62% | -1.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 6.30% | 510.90% | -179.64% | -120.62% | 299.62% |
| Change in Net Operating Assets | 164.93% | 59.74% | 54.71% | -404.15% | 153.38% |
| Cash from Operations | 6.61% | 100.45% | 65.38% | -63.50% | 186.20% |
| Capital Expenditure | -8.35% | -26.10% | 8.67% | -22.03% | -22.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 89.86% | -726.75% | -848.03% | 79.67% | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.94% | -598.50% | -269.70% | 58.41% | -152.55% |
| Cash from Investing | 46.10% | -293.16% | -39.75% | 6.03% | -62.60% |
| Total Debt Issued | -142.44% | 601.41% | 887,600.00% | -100.00% | -- |
| Total Debt Repaid | 100.00% | -16.40% | -249,900.00% | 99.99% | -596.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 76.45% | 32.05% | -56.26% | -112.95% | -2.31% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.32% | 0.13% | -15.05% | 0.04% | 0.07% |
| Other Financing Activities | -325.00% | 99.32% | -2,254.58% | 13.45% | 6.45% |
| Cash from Financing | -185.68% | 342.82% | -20.54% | -642.15% | 142.65% |
| Foreign Exchange rate Adjustments | 207.69% | -177.61% | 199.85% | -309.69% | -88.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -210.82% | 284.69% | 21.30% | -139.33% | 2,167.14% |